SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/252559"
 

Search: onr:"swepub:oai:gup.ub.gu.se/252559" > The effects of diff...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

The effects of different familial Alzheimer's disease mutations on APP processing in vivo

Thordardottir, S. (author)
Karolinska Institutet
Stahlbom, A. K. (author)
Almkvist, O. (author)
Karolinska Institutet
show more...
Thonberg, H. (author)
Karolinska Institutet
Eriksdotter, M. (author)
Karolinska Institutet
Zetterberg, Henrik, 1973 (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Blennow, Kaj, 1958 (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Graff, C. (author)
Karolinska Institutet
show less...
 (creator_code:org_t)
2017-02-16
2017
English.
In: Alzheimers Research & Therapy. - : Springer Science and Business Media LLC. - 1758-9193. ; 9:9
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background: Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer's disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may serve as a model for the sporadic form of AD. In FAD the diagnosis of AD is reliable and presymptomatic individuals carrying FAD mutations can give valuable insights into the earliest stages of the disease where therapeutic interventions are thought to be the most effective. Methods: In the current cross-sectional study, products of APP processing (e.g., sAPP alpha, sAPP beta, A beta(38), A beta(40) and A beta(42)) were measured in the cerebrospinal fluid (CSF) of individuals carrying one of three FAD mutations, APPswe (p. KM670/671NL), APParc (p.E693G) and PSEN1 (p.H163Y), as well as in non-mutation carriers from the same families. Results: We observed pathological APP processing in presymptomatic carriers of FAD mutations, with different profiles of APP and A beta isoforms in the three mutation carrier groups, APPswe (p. KM670/671NL), APParc (p.E693G) and PSEN1 (p.H163Y), except for the well-established decrease in CSF A beta(42) that was found with all mutations. Conclusions: These findings add to the current evidence that AD pathophysiology differs between disease-causing mutations and can be monitored in the presymptomatic disease stage by CSF analyses. This may also be important from a therapeutic standpoint, by opening a window to monitor effects of disease-modifying drugs on AD pathophysiology.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Medicinsk genetik (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Medical Genetics (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Keyword

Alzheimer's disease
Amyloid precursor protein
Biomarkers
Cerebrospinal fluid
Genetics
amyloid-precursor protein
cerebrospinal-fluid levels
alpha-secretase
biomarkers
gene
diagnosis
consensus
pattern
plasma
onset
Neurosciences & Neurology

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view